Filtered By:
Management: WHO
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 134 results found since Jan 2013.
Status of New Vaccine Introduction - Worldwide, 2016-2021
This report describes the status of introductions globally for eight World Health Organization (WHO)-recommended new and underutilized vaccines, comprising 10 individual vaccine antigens. By 2021, among 194 countries worldwide, 33 (17%) provided all of these 10 WHO-recommended antigens as part of their routine immunization schedules; only one low-income country had introduced all of these recommended vaccines. Universal hepatitis B birth dose; human papillomavirus vaccine; rotavirus vaccine; and diphtheria, tetanus, and pertussis-containing vaccine first booster dose have been introduced by 57%, 59%, 60%, and 72% of all co...
Source: MMWR Morb Mortal Wkl... - July 6, 2023 Category: Epidemiology Authors: Gurpreet Kaur Rebecca M Casey Jaymin C Patel Paul Bloem Jenny A Walldorf Terri B Hyde Source Type: research
Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery
PLOS Glob Public Health. 2022 Apr 6;2(4):e0000101. doi: 10.1371/journal.pgph.0000101. eCollection 2022.ABSTRACTThe World Health Organization (WHO) recommends the human papillomavirus (HPV) vaccine for girls aged 9-14 years for cervical cancer prevention and encourages vaccinating multiple cohorts in the first year to maximize impact. The HPV vaccine was introduced nationwide in Zimbabwe in 2018 through a 1-week school-based campaign to multiple cohorts (all girls 10-14 years old), followed by a single cohort (grade 5 girls in school and age 10 girls out-of-school) in 2019. During the 2019 campaign, the multiple cohort's se...
Source: Cancer Control - March 24, 2023 Category: Cancer & Oncology Authors: Julie Garon Carlton Joan Marembo Portia Manangazira Maxwell Rupfutse Adelaide Shearley Egnes Makwabarara Anna Hidle Anagha Loharikar Source Type: research
The Cost Analysis of Human Papillomavirus Vaccination Program in Indonesia
CONCLUSIONS: The implementation of demonstration program in Surabaya, Makassar, and Manado cities was considerably succeed. Any prediction related to the cost of implementation of HPV vaccination in Indonesia can be calculated and used to advocate regional or national government.PMID:36934486 | DOI:10.1016/j.vhri.2023.01.005
Source: Cancer Control - March 19, 2023 Category: Cancer & Oncology Authors: Didik Setiawan Andi Nurul Annisa None Lianawati Raymond C W Hutubessy Karene Hoi Ting Yeung Source Type: research
Highlights into historical and current immune interventions for cancer
Int Immunopharmacol. 2023 Feb 27;117:109882. doi: 10.1016/j.intimp.2023.109882. Online ahead of print.ABSTRACTImmunotherapy is an additional pillar when combined with traditional standards of care such as chemotherapy, radiotherapy, and surgery for cancer patients. It has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapies, including adoptive cellular therapy (ACT) and checkpoint inhibitors (CPIs), can induce durable clinical responses. However, their efficacies vary, and only subsets of cancer patients benefit from their use. In this review, we address three goal...
Source: International Immunopharmacology - February 27, 2023 Category: Allergy & Immunology Authors: Kathryn Cole Zaid Al-Kadhimi James E Talmadge Source Type: research
Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis
Vaccine. 2023 Feb 14:S0264-410X(23)00160-3. doi: 10.1016/j.vaccine.2023.02.025. Online ahead of print.ABSTRACTGlobally, gender-neutral Human Papillomavirus (HPV) vaccination programmes are gaining traction. Although cervical cancer remains the most prevalent, other HPV-related cancers are increasingly recognised as important, especially among men who have sex with men. We assessed if including adolescent boys in Singapore's school-based HPV vaccination programme is cost-effective from the healthcare perspective. We adapted a World Health Organization-supported model, Papillomavirus Rapid Interface for Modelling and Economi...
Source: Vaccine - February 16, 2023 Category: Allergy & Immunology Authors: Muhammad Taufeeq Wahab Rayner Kay Jin Tan Alex R Cook Kiesha Prem Source Type: research
